-+ 0.00%
-+ 0.00%
-+ 0.00%

Tango Therapeutics Swings to Q3 Net Loss of $68.39 Million

PUBT·11/09/2026 12:07:16
Tango Therapeutics Swings to Q3 Net Loss of $68.39 Million
  • Tango Therapeutics swung to a third-quarter 2026 net loss of $68.39 million from year-earlier net income of $15.88 million.
  • Collaboration revenue fell to none from $53.81 million a year earlier following the Gilead collaboration’s conclusion in 2025.
  • Research and development expenses rose 59% to $48.93 million year-over-year; general and administrative expenses more than tripled to $29.19 million.
  • Cash, cash equivalents and marketable securities totaled $977.5 million at September 30, 2026.
  • A Phase 3 trial of vopimetostat with daraxonrasib for front-line MTAP-deleted pancreatic cancer is planned for the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9873036) on November 09, 2026, and is solely responsible for the information contained therein.